Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

LRMR

Larimar Therapeutics Inc

Feb 12 • 04:00PM ET

3.21

-0.13 -3.89 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN FOLD QURE RPTX ARWR ONCT SRPT CRSP RIGL

| Held by: VTI IWM VXF IWN IBB VTWO DFAS IWC AVSC FSCC

Index	RUT	P/E	-	EPS (ttm)	-1.93	Insider Own	45.67%	Shs Outstand	85.59M	Perf Week	4.56%
Market Cap	274.75M	Forward P/E	-	EPS next Y	-1.82	Insider Trans	0.00%	Shs Float	46.50M	Perf Month	-3.60%
Enterprise Value	103.66M	PEG	-	EPS next Q	-0.49	Inst Own	57.98%	Short Float	18.85%	Perf Quarter	-11.57%
Income	-132.00M	P/S	-	EPS this Y	-47.86%	Inst Trans	12.60%	Short Ratio	7.02	Perf Half Y	-13.71%
Sales	0.00M	P/B	1.98	EPS next Y	6.84%	ROA	-64.96%	Short Interest	8.77M	Perf YTD	-15.75%
Book/sh	1.62	P/C	1.57	EPS next 5Y	-5.48%	ROE	-78.24%	52W High	5.37 -40.22%	Perf Year	-0.62%
Cash/sh	2.05	P/FCF	-	EPS past 3/5Y	23.60% 50.78%	ROIC	-92.80%	52W Low	1.61 99.38%	Perf 3Y	-51.80%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.81% 7.03%	Perf 5Y	-83.50%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-67.41%	Oper. Margin	-	ATR (14)	0.23	Perf 10Y	-95.87%
Dividend Ex-Date	-	Quick Ratio	4.06	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.90	Recom	1.09
Dividend Gr. 3/5Y	- -	Current Ratio	4.06	EPS Q/Q	-150.80%	SMA20	-5.67%	Beta	1.02	Target Price	15.40
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-9.77%	Rel Volume	0.35	Prev Close	3.34
Employees	65	LT Debt/Eq	0.02	Earnings	Nov 05 BMO	SMA200	-7.28%	Avg Volume	1.25M	Price	3.21
IPO	Jun 19, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-51.10% -	Trades		Volume	446,119	Change	-3.89%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-25	Initiated	Truist	Buy	$18
Oct-16-24	Initiated	Oppenheimer	Outperform	$26
Oct-03-24	Initiated	Wedbush	Outperform	$22
Oct-02-24	Initiated	H.C. Wainwright	Buy	$15
Sep-04-24	Initiated	Robert W. Baird	Outperform	$16
Apr-03-24	Initiated	Leerink Partners	Outperform	$25
Nov-17-23	Upgrade	Citigroup	Neutral → Buy	$4.50
Oct-19-22	Initiated	Guggenheim	Buy	$12
Feb-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Feb-10-21	Initiated	JMP Securities	Mkt Outperform
Feb-01-21	Initiated	William Blair	Outperform	$29

Show Previous Ratings

Dec-18-25 08:00AM	Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-05-25 07:14AM	Larimar: Q3 Earnings Snapshot (Associated Press Finance) -15.26%
07:00AM	Larimar Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-22-25 05:47PM	The Best AI for Picking Stocks, Ranked by Performance (MarketBeat) -8.39%
Oct-09-25 04:14PM	Lost Money on Larimar Therapeutics, Inc. (LRMR)? Possible Fraud - Contact Levi & Korsinsky Today (Newsfile) -5.60%
07:00AM	Loading…
Sep-29-25 07:00AM	Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia (GlobeNewswire) -33.66%
Sep-28-25 05:00PM	Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia (GlobeNewswire)
Aug-14-25 07:13AM	Larimar: Q2 Earnings Snapshot (Associated Press Finance) +14.52%
07:00AM	Larimar Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 04:15PM	Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jul-29-25 11:50PM	Larimar Therapeutics Announces Pricing of Underwritten Public Offering (GlobeNewswire)
04:01PM	Larimar Therapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire)
Jul-17-25 09:11AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics (Zacks)
Jul-16-25 09:01AM	5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats (Zacks)
Jul-08-25 07:00AM	Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire)
07:00AM	Loading…
Jun-23-25 07:00AM	Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program (GlobeNewswire) -6.56%
Jun-20-25 04:05PM	Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia (GlobeNewswire) -5.47%
May-21-25 11:22AM	Larimar Therapeutics, Inc.'s (LRMR): Analysts See 957% Upside Potential (Insider Monkey) -6.31%
Apr-30-25 07:00AM	Larimar Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire) +10.88%
Apr-04-25 01:12PM	Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts (Seeking Alpha)
Mar-24-25 07:00AM	Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -10.24%
Mar-03-25 04:05PM	Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire) -12.54% +5.28%
Jan-23-25 04:05PM	Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia (GlobeNewswire)
Dec-17-24 07:20AM	Larimar Therapeutics announces initial data from OLE study of nomlabofusp (TipRanks) -10.56%
Dec-16-24 07:00AM	Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study and Progress Across Nomlabofusp Program for Friedreich's Ataxia (GlobeNewswire) -21.72%
07:00AM	Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreichs Ataxia (GlobeNewswire)
Nov-18-24 07:00AM	Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 (GlobeNewswire) -7.92%
Oct-30-24 07:00AM	Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results (GlobeNewswire) +8.74%
Sep-19-24 07:00AM	Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research (GlobeNewswire)
Aug-27-24 08:00AM	Larimar Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Aug-07-24 07:00AM	Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -6.54%
May-30-24 04:05PM	Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia (GlobeNewswire) +12.68%
May-22-24 11:25AM	Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study (Zacks)
May-21-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +8.53%
May-20-24 04:05PM	Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia (GlobeNewswire)
May-09-24 01:55PM	LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results (GlobeNewswire)
Mar-20-24 01:32PM	Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks (Insider Monkey)
Mar-14-24 09:53PM	LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.51%
05:32PM	Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
04:05PM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development (GlobeNewswire)
Mar-11-24 04:05PM	Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire) -15.39%
Mar-06-24 04:05PM	Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-20-24 01:47PM	Hedge Fund and Insider Trading News: Bill Ackman, George Soros, Arkhouse Management, TYR Capital, Borea Asset Management, Larimar Therapeutics, Inc. (LRMR), and More (Insider Monkey) -5.63%
Feb-19-24 01:48PM	Hedge Fund and Insider Trading News: Bill Ackman, David Tepper, Mark Yusko, Elliott Management, Conestoga Capital Advisors, Larimar Therapeutics Inc (LRMR), Agree Realty Corporation (ADC), and More (Insider Monkey)
Feb-16-24 04:20PM	Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.63%
Feb-14-24 06:15AM	Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock (GlobeNewswire) +36.84%
Feb-13-24 04:18PM	Larimar Therapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire) +11.62%
Feb-12-24 07:00AM	Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire)
Nov-14-23 07:00AM	Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results (GlobeNewswire) +7.11%
Nov-01-23 04:05PM	Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference (GlobeNewswire)
Oct-03-23 04:05PM	Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors (GlobeNewswire) -5.83%
Aug-31-23 04:05PM	Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference (GlobeNewswire)
Aug-10-23 07:00AM	Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Aug-07-23 09:22AM	Larimar Therapeutics Insiders Placed Bullish Bets Worth US$1.2m (Simply Wall St.) -7.19%
Jul-25-23 09:59AM	These 2 Strong Buy Penny Stocks Could Go Boom, Say Analysts (TipRanks) +7.67%
07:00AM	Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial (GlobeNewswire)
Jul-17-23 04:05PM	Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer (GlobeNewswire)
Jun-21-23 04:05PM	Larimar Therapeutics Set to Join Russell 3000® Index (GlobeNewswire)
May-15-23 07:00AM	Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trials 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreichs Ataxia and First Quarter 2023 Financial Results (GlobeNewswire) -29.05%
Mar-28-23 04:05PM	Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days (GlobeNewswire)
Mar-14-23 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results (GlobeNewswire)
Feb-07-23 04:05PM	Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer (GlobeNewswire) +6.52% +7.99%
Nov-21-22 04:05PM	Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-10-22 07:00AM	Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results (GlobeNewswire)
Nov-07-22 04:05PM	Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day (GlobeNewswire)
Oct-20-22 08:00AM	Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601 (GlobeNewswire)
Oct-19-22 04:05PM	Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research (GlobeNewswire)
Sep-16-22 01:00PM	Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares (GlobeNewswire) -5.04%
Sep-14-22 07:04AM	Larimar Therapeutics Announces $70 Million Underwritten Offering (GlobeNewswire) +15.56%
07:01AM	Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreichs Ataxia Patients (GlobeNewswire)
Aug-11-22 04:05PM	Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results (GlobeNewswire) +7.07%
Jul-28-22 04:05PM	Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders (GlobeNewswire)
Jun-28-22 08:00AM	Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts (GlobeNewswire)
06:05AM	We're Keeping An Eye On Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Rate (Simply Wall St.)
Jun-02-22 08:00AM	Larimar Therapeutics Announces Upcoming Scientific Conference Presentations (GlobeNewswire)
May-19-22 08:00AM	Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinsons Disease and Movement Disorders Congress (GlobeNewswire)
May-12-22 07:00AM	Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results (GlobeNewswire) -7.91%
Apr-29-22 06:27AM	Despite recent gains, Larimar Therapeutics, Inc. (NASDAQ:LRMR) insiders are still down US$273k after purchasing last year (Simply Wall St.) -5.84%
Apr-13-22 10:40AM	Down 21.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR) (Zacks)
Mar-25-22 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results (GlobeNewswire)
Feb-16-22 11:57AM	Larimar Therapeutics' stock plunges on FDA decision; could implement cost-cutting measures (American City Business Journals)
Feb-14-22 04:01PM	Larimar Therapeutics Provides Update on CTI-1601 Clinical Program (GlobeNewswire) -52.09%
Jan-19-22 06:53AM	Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-22-21 07:00AM	Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference (GlobeNewswire)
Nov-20-21 08:40AM	In spite of Larimar Therapeutics, Inc.'s recent pullback, insiders still gained about US$85k after buying earlier this year. (Simply Wall St.)
Nov-15-21 07:00AM	Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference (GlobeNewswire)
Nov-12-21 07:00AM	Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results (GlobeNewswire) -8.72%
Sep-16-21 08:00AM	Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event (GlobeNewswire) -7.48%
Sep-02-21 04:01PM	Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire) +5.81%
Aug-22-21 10:12AM	What You Need To Know About Larimar Therapeutics, Inc.'s (NASDAQ:LRMR) Investor Composition (Simply Wall St.)
Aug-19-21 07:00AM	Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress (GlobeNewswire)
Aug-12-21 07:00AM	Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results (GlobeNewswire) +17.79%
Aug-09-21 08:48AM	Why Larimar (LRMR) Might Surprise This Earnings Season (Zacks)
Jul-23-21 12:00PM	Larimar (LRMR) Upgraded to Buy: Here's Why (Zacks)
Jul-08-21 04:01PM	Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021 (GlobeNewswire)
Jun-11-21 07:00AM	Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
Jun-05-21 07:55PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (Newsfile)
Jun-02-21 10:56PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (GlobeNewswire)
Jun-01-21 04:55AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (PR Newswire)

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flynn James E	Director	Jul 31 '25	Buy	3.20	9,375,000	30,000,000	9,538,945	Aug 04 06:28 PM

OSUR Orasure Technologies Inc daily Stock Chart

Peers: ABT LH BDX DGX BAX HOLX QDEL MYGN FMS MBAI

| Held by: VTI IWM VXF IWN SCHA DFAT VTWO DFAS SVAL IWC

Index	RUT	P/E	-	EPS (ttm)	-0.81	Insider Own	5.70%	Shs Outstand	72.27M	Perf Week	2.56%
Market Cap	200.85M	Forward P/E	-	EPS next Y	-0.76	Insider Trans	0.05%	Shs Float	67.64M	Perf Month	7.69%
Enterprise Value	-2.17M	PEG	-	EPS next Q	-0.20	Inst Own	86.46%	Short Float	5.75%	Perf Quarter	13.82%
Income	-60.24M	P/S	1.60	EPS this Y	-232.69%	Inst Trans	-4.05%	Short Ratio	5.79	Perf Half Y	-1.75%
Sales	125.70M	P/B	0.56	EPS next Y	12.14%	ROA	-13.58%	Short Interest	3.89M	Perf YTD	15.70%
Book/sh	5.01	P/C	0.93	EPS next 5Y	-	ROE	-15.30%	52W High	4.22 -33.65%	Perf Year	-25.13%
Cash/sh	3.02	P/FCF	-	EPS past 3/5Y	6.40% -	ROIC	-16.14%	52W Low	2.08 34.62%	Perf 3Y	-43.78%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-7.35% 3.75%	Gross Margin	37.19%	Volatility	5.23% 5.14%	Perf 5Y	-80.23%
Dividend TTM	-	EV/Sales	-0.02	EPS Y/Y TTM	-620.21%	Oper. Margin	-49.99%	ATR (14)	0.14	Perf 10Y	-55.34%
Dividend Ex-Date	-	Quick Ratio	6.20	Sales Y/Y TTM	-43.95%	Profit Margin	-47.92%	RSI (14)	55.24	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	7.03	EPS Q/Q	-210.93%	SMA20	1.30%	Beta	0.90	Target Price	4.50
Payout	-	Debt/Eq	0.04	Sales Q/Q	-32.14%	SMA50	7.51%	Rel Volume	0.72	Prev Close	2.82
Employees	501	LT Debt/Eq	0.03	Earnings	Feb 25 AMC	SMA200	-1.52%	Avg Volume	671.16K	Price	2.80
IPO	Nov 17, 1986	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.00% -7.01%	Trades		Volume	481,222	Change	-0.71%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-03-23	Resumed	Evercore ISI	In-line	$5
Sep-22-21	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-21-20	Initiated	Evercore ISI	Outperform	$22
Aug-10-20	Initiated	JP Morgan	Neutral	$18
Aug-10-20	Initiated	Citigroup	Buy	$18
Aug-07-20	Upgrade	Raymond James	Mkt Perform → Outperform	$16
Jun-25-20	Initiated	Lake Street	Buy	$19
Apr-21-20	Resumed	Stephens	Equal-Weight	$14
Oct-23-18	Resumed	Raymond James	Mkt Perform
Jul-16-18	Downgrade	Stephens	Overweight → Equal-Weight
Nov-02-17	Downgrade	Jefferies	Buy → Hold
Feb-09-17	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-13-16	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-05-15	Reiterated	Mizuho	Buy	$12 → $8
May-07-15	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jan-23-15	Reiterated	Mizuho	Buy	$10 → $12
Jun-12-14	Reiterated	Canaccord Genuity	Buy	$10 → $11
Jun-11-14	Reiterated	Mizuho	Buy	$9 → $10
Dec-21-12	Initiated	Mizuho	Buy	$9
Aug-08-12	Upgrade	Barrington Research	Mkt Perform → Outperform	$12.50

Show Previous Ratings

Feb-10-26 08:05AM	OraSure to Launch OraQuick HIV Self-Test in Canada (GlobeNewswire)
Feb-09-26 04:15PM	OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th (GlobeNewswire)
Feb-04-26 06:15PM	Phibro Animal Health (PAHC) Q2 Earnings and Revenues Surpass Estimates (Zacks) -5.86%
Jan-15-26 01:00PM	OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital (GlobeNewswire)
08:30AM	Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors (Business Wire)
11:39AM	Loading…
Jan-06-26 11:39AM	OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device (Zacks)
Jan-05-26 08:00AM	OraSure Submits CT/NG Molecular Self-Test and Colli-Pee Urine Collection Device for FDA Review (GlobeNewswire)
Dec-17-25 01:23PM	OraSure Technologies Issues Statement Regarding Altai Capital's Intent to Nominate Director Candidates (GlobeNewswire)
08:00AM	Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors (Business Wire)
Nov-17-25 07:45AM	OraSure to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-06-25 12:07AM	OraSure Technologies Inc (OSUR) Q3 2025 Earnings Call Highlights: Navigating Market Challenges ... (GuruFocus.com) -6.61%
Nov-05-25 06:50PM	OraSure Technologies (OSUR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
05:49PM	OraSure: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	OraSure Announces Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 08:41AM	OraSure Technologies Inc (OSUR) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
07:50AM	Loading…
07:50AM	InfuSystems Holdings, Inc. (INFU) Tops Q3 Earnings Estimates (Zacks)
Oct-29-25 07:30AM	OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th (GlobeNewswire)
Oct-28-25 04:22PM	OraSure Technologies Appoints Steven K. Boyd to its Board of Directors (GlobeNewswire)
Oct-09-25 08:10AM	Tilray Brands, Inc. (TLRY) Reports Break-Even Earnings for Q1 (Zacks)
Sep-12-25 06:59PM	OraSure, Central Pacific, and More Stocks See Action From Activist Investors (Barrons.com)
Sep-09-25 06:19AM	Exclusive-Altai Capital lays groundwork for board fight at OraSure Technologies, sources say (Reuters)
Aug-06-25 03:28AM	OraSure Technologies Inc (OSUR) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) -8.49%
Aug-05-25 06:30PM	OraSure Technologies (OSUR) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
05:25PM	OraSure: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	OraSure Announces Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 10:07AM	Earnings To Watch: OraSure Technologies Inc (OSUR) Reports Q2 2025 Result (GuruFocus.com)
07:05AM	OraSure Appoints Anne Messing as Chief Commercial Officer (GlobeNewswire)
Jul-21-25 04:05PM	OraSure to Announce Second Quarter 2025 Financial Results and Host Earnings Call on August 5th (GlobeNewswire) +6.15%
Jul-14-25 12:03PM	OraSure Technologies received takeover bid from industry entrepreneur, sources say (Reuters)
Jul-10-25 07:05AM	OraSure Launches Novel Blood Collection Device for Proteomic Research (GlobeNewswire)
11:35AM	Loading…
May-20-25 11:35AM	Evercore says 23andMe buyout removes downside case for OraSure (TipRanks) +6.46%
May-14-25 08:00AM	Targeted Genomics Announces Commercial Collaboration with OraSure Technologies for Direct to Consumer (DTC) Celiac Genetic Testing (GlobeNewswire) -6.04%
May-08-25 09:50AM	Q1 2025 OraSure Technologies Inc Earnings Call (Thomson Reuters StreetEvents) -6.81%
03:33AM	OraSure Technologies Inc (OSUR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-07-25 08:02PM	Orasure technologies outlines Q2 2025 revenue guidance of $28.5M-$32.5M amid new product launches and customer expansions (Seeking Alpha)
08:01PM	OraSure Technologies, Inc. (OSUR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:55PM	OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:47PM	OraSure: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	OraSure Announces First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 05:45PM	Envista (NVST) Beats Q1 Earnings and Revenue Estimates (Zacks)
Apr-30-25 03:47PM	OraSure Technologies: Historically Cheap (Seeking Alpha)
Apr-23-25 04:05PM	OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th (GlobeNewswire)
07:40AM	Boston Scientific (BSX) Q1 Earnings and Revenues Top Estimates (Zacks)
Apr-10-25 11:35AM	GE HealthCare (GEHC) Surges 10.6%: Is This an Indication of Further Gains? (Zacks) -6.96%
Apr-02-25 03:35PM	OraSure Technologies, Inc. (OSUR): Insider Were Buying In Q1 2025 (Insider Monkey)
Mar-24-25 07:30AM	OraSure Announces $40 Million Stock Repurchase Program (GlobeNewswire) +6.40%
Feb-26-25 09:03AM	Q4 2024 OraSure Technologies Inc Earnings Call (Thomson Reuters StreetEvents) -23.50%
02:16AM	OraSure Technologies Inc (OSUR) Q4 2024 Earnings Call Highlights: Strong Core Revenue Growth ... (GuruFocus.com)
Feb-25-25 06:10PM	OraSure Technologies (OSUR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:15PM	OraSure: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	OraSure Reports Fourth Quarter 2024 Financial Results (GlobeNewswire)
01:50AM	OraSure Technologies Inc (OSUR) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-14-25 08:45AM	OraSure to Announce Fourth Quarter 2024 Financial Results and Host Earnings Call on February 25th (GlobeNewswire)
Jan-27-25 12:00PM	OraSure (OSUR) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Jan-23-25 09:40AM	Should Value Investors Buy OraSure Technologies (OSUR) Stock? (Zacks)
Jan-07-25 04:05PM	OraSure to Present at the J.P Morgan Healthcare Conference (GlobeNewswire)
09:40AM	Are Investors Undervaluing OraSure Technologies (OSUR) Right Now? (Zacks)
08:50AM	CORRECTION - OraQuick HIV Self-Test Now Approved for Use in Adolescents (GlobeNewswire)
07:05AM	OraQuick HIV Self-Test Now Approved for Use in Adolescents (GlobeNewswire)
Dec-19-24 04:02PM	OraSure Technologies Acquires Sherlock Biosciences (GlobeNewswire)
Dec-02-24 07:05AM	OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test (GlobeNewswire)
Nov-28-24 09:40AM	Is OraSure Technologies (OSUR) Stock Undervalued Right Now? (Zacks)
Nov-18-24 04:05PM	OraSure to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-12-24 09:40AM	Is OraSure Technologies (OSUR) a Great Value Stock Right Now? (Zacks)
Nov-07-24 10:00AM	OraSure Technologies Inc (OSUR) Q3 2024 Earnings Call Highlights: Revenue Growth in Diagnostics ... (GuruFocus.com)
Nov-06-24 05:55PM	OraSure Technologies (OSUR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:58PM	OraSure: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	OraSure Reports Q3 '24 Revenue of $39.9 Million (GlobeNewswire)
Nov-05-24 08:01AM	OraSure Technologies Inc (OSUR) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-22-24 04:05PM	OraSure to Announce Third Quarter 2024 Financial Results and Host Earnings Call on November 6th (GlobeNewswire)
Oct-13-24 02:11PM	OraSure Technologies Inc. (OSUR): Among the Most Profitable Penny Stocks to Invest In (Insider Monkey)
Oct-04-24 05:03PM	Neuberger Berman Group LLC Expands Stake in OraSure Technologies Inc (GuruFocus.com)
Sep-12-24 01:25AM	BlackRock Inc. Increases Stake in OraSure Technologies Inc. (GuruFocus.com)
Sep-09-24 07:05AM	OraSure Technologies Elects Jack Kenny to the Board of Directors (GlobeNewswire)
Aug-07-24 10:16AM	Q2 2024 OraSure Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-06-24 06:25PM	OraSure Technologies (OSUR) Tops Q2 Earnings and Revenue Estimates (Zacks)
05:20PM	OraSure: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	OraSure Reports Q2 24 Revenue of $54.3 Million (GlobeNewswire)
Jul-22-24 04:05PM	OraSure to Announce Second Quarter 2024 Financial Results and Host Earnings Call on August 6th (GlobeNewswire)
Jun-27-24 07:05AM	OraSure Technologies Supports National HIV Testing Day (GlobeNewswire)
Jun-07-24 06:09PM	KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
May-13-24 10:47AM	JPMorgan Adjusts OraSure Technologies Price Target to $6 From $7, Maintains Neutral Rating (MT Newswires) +6.17%
May-10-24 03:04PM	OraSure Technologies Inc (OSUR) Q1 2024 Earnings: Revenue Decline Amidst Strategic Restructuring (GuruFocus.com)
May-09-24 01:54PM	OraSure Technologies, Inc. (NASDAQ:OSUR) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:29AM	Q1 2024 OraSure Technologies Inc Earnings Call (Thomson Reuters StreetEvents)
03:48AM	OraSure Technologies Inc (OSUR) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-08-24 08:57PM	OSUR Stock Earnings: OraSure Technologies Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:20PM	OraSure Technologies (OSUR) Q1 Earnings Meet Estimates (Zacks)
05:17PM	OraSure: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	OraSure Reports Q1 '24 Revenue of $54.1 Million (GlobeNewswire)
Apr-22-24 08:00AM	OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th (GlobeNewswire)
Apr-18-24 11:30AM	Wall Street Favorites: 3 Under-$10 Stocks With Strong Buy Ratings for April 2024 (InvestorPlace)
Mar-21-24 08:31AM	NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board (Business Wire)
Feb-28-24 09:23AM	Q4 2023 OraSure Technologies Inc Earnings Call (Thomson Reuters StreetEvents) +9.96%
08:55AM	OraSure Technologies, Inc. (NASDAQ:OSUR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 05:11PM	OraSure: Q4 Earnings Snapshot (Associated Press Finance)
04:48PM	OraSure Technologies Inc (OSUR) Reports Q4 Revenue Decline Amidst Strategic Growth Efforts (GuruFocus.com)
04:05PM	OraSure Reports Q4 '23 Revenue of $75.9 Million (GlobeNewswire)
Feb-13-24 04:05PM	OraSure to Announce Fourth Quarter 2023 Financial Results and Host Earnings Call on February 27th (GlobeNewswire) -5.03%
Feb-01-24 06:42PM	3 Strong Buy Stocks Under $10: January 2024 (InvestorPlace)

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offers oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in 2000 in and is headquartered in Bethlehem, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mara Aspinall	Board	Dec 04 '25	Proposed Sale	2.51	89,716	225,000		Dec 04 01:45 PM
Gagliano Nancy J	Director	Nov 28 '25	Buy	2.37	2,100	4,982	160,254	Dec 02 04:16 PM
Gagliano Nancy J	Director	Feb 27 '25	Buy	3.08	12,750	39,270	91,524	Mar 03 09:08 AM
EGLINTON MANNER CARRIE	President & CEO	Feb 28 '25	Buy	3.49	28,670	100,027	1,288,334	Mar 03 09:07 AM
EGLINTON MANNER CARRIE	President & CEO	Feb 27 '25	Buy	3.15	78,625	247,378	1,259,664	Feb 27 09:14 PM
Kenny John P.	Director	Feb 27 '25	Buy	3.17	47,659	151,217	70,915	Feb 27 09:14 PM
McGrath Kenneth J	Chief Financial Officer	Feb 27 '25	Buy	3.15	64,000	201,683	371,013	Feb 27 09:14 PM
Marmora Lelio	Director	Feb 27 '25	Buy	3.06	7,000	21,420	67,720	Feb 27 04:19 PM

LRMR

Larimar Therapeutics Inc

OSUR

Orasure Technologies Inc

Upgrade your FINVIZ experience